Diagonal Bio Ab Stock Beta
| DIABIO Stock | 0.03 0 8.84% |
Diagonal Bio AB fundamentals help investors to digest information that contributes to Diagonal Bio's financial success or failures. It also enables traders to predict the movement of Diagonal Stock. The fundamental analysis module provides a way to measure Diagonal Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Diagonal Bio stock.
Diagonal |
Diagonal Bio AB Company Beta Analysis
Diagonal Bio's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Diagonal Bio AB has a Beta of 0.0. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Beta (which currently averages 0.0) industry. This indicator is about the same for all Sweden stocks average (which is currently at 0.0).
Diagonal Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Diagonal Bio's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Diagonal Bio could also be used in its relative valuation, which is a method of valuing Diagonal Bio by comparing valuation metrics of similar companies.Diagonal Bio is currently under evaluation in beta category among its peers.
Diagonal Fundamentals
| Return On Equity | -0.52 | |||
| Return On Asset | -0.27 | |||
| Operating Margin | (3.67) % | |||
| Current Valuation | 112.69 K | |||
| Shares Outstanding | 34.77 M | |||
| Shares Owned By Insiders | 14.74 % | |||
| Price To Book | 0.50 X | |||
| Price To Sales | 3.26 X | |||
| Revenue | 407 K | |||
| Gross Profit | (85 K) | |||
| EBITDA | (11.66 M) | |||
| Net Income | (11.66 M) | |||
| Book Value Per Share | 2.39 X | |||
| Cash Flow From Operations | (10.94 M) | |||
| Earnings Per Share | (1.83) X | |||
| Market Capitalization | 21.97 M | |||
| Total Asset | 36.01 M | |||
| Net Asset | 36.01 M |
About Diagonal Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Diagonal Bio AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Diagonal Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Diagonal Bio AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Diagonal Stock
Diagonal Bio financial ratios help investors to determine whether Diagonal Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diagonal with respect to the benefits of owning Diagonal Bio security.